Dubai-based Bioventure, Egypt’s Minapharm Pharmaceuticals and German pharma MiGenTra have agreed to commercialize multiple biosimilars developed and manufactured by Alvotech (Nasdaq: ALVO), in 19 countries in Africa and the Middle East.
Minapharm and MiGenTra will share responsibilities to file, launch and commercialize Alvotech's portfolio of licensed biosimilars in these countries once the candidates receive regulatory approval.
"Provide patients across Africa and the Middle East with a unique set of high quality and affordable biological medicines"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze